Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6685942B1 · kind B1 · utility
45Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 1997 |
| Grant date | Feb 3, 2004 |
| Priority date | — |
| Expiry date | Aug 26, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.